Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AXS-05 in treatment resistant depression
NCT04634669Phase 2Terminated
- Sponsor
- Axsome Therapeutics, Inc.
- Start
- Sep 2020
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dextromethorphan + bupropion in major depressive disorder (MDD), sponsored by Axsome Therapeutics, Inc.. Started Sep 2020; status: terminated.
02
Drugs
dextromethorphan + bupropion
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04634669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04634669.